Zusammenfassung
Hauptgruppen der Calciumantagonisten sind die Dihydropyridine und die relativ stärker kardiodepressiv wirkenden Substanzen Verapamil und Diltiazem.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Arzneimittelkommission der deutschen Ärzteschaft (1997): Calciumantagonisten vom 1,4-Dihydropyridin-Typ. Dtsch Ärztebl 22: C-1122-C–1123
Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (2014): Nationale VersorgungsLeitlinie Chronische KHK. Langfassung, 3. Auflage, Version 1, Dezember 2014, AWMF-Register-Nr.: nvl-004. Internet: http://www.leitlinien.de/nvl/khk/
Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators (2014): A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 370:1393–1401
Cohn JN, Ziesche SM, Loss LE, Anderson GF, V-HeFT Study Group (1995): Effect of felodipine on short-term exercise and neurohormone and long-term mortality in heart failure: Results of V-HeFT VIII. Circulation 92: 1–143
Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristins- son A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT Investigators
(2005): Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366: 895–906
Deutsche Gesellschaft für Kardiologie (2003): Leitlinien zur Behandlung der chronischen koronaren Herzkrankheit. Z Kardiol 92: 501–521
Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M, Symplicity HTN–2
Investigatorsl (2010): Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376: 1903–1909
Heidenreich PA, McDonald KM, Hastie T, Fadel B, Hagan V, Lee BK, Hlatky MA (1999): Meta-analysis of trials comparing b-blockers, calcium antagonists, and nitrates for stable angina. JAMA 281: 1927–1936
Makarounas-Kirchmann K, Glover-Koudounas S, Ferrari P (2009): Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers. Clin Ther 31: 1652–1663
Mancia G, Coca A, Chazoval, Girerd X, Haller H, Pauletto P, Pupek-Musialik D, Svyshchenko Y; FELT investigators (2014): Effects on office and home blood pressure of the lercanidipineenalapril combination in patients with Stage 2 hypertension: a European randomized, controlled clinical trial. J Hypertens 32: 1700–1707
Muntner P, Levitan EB, Lynch AI, Simpson LM, Whittle J, Davis BR, Kostis JB, Whelton PK, Oparil S (2014): Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit variability of blood pressure: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens 16: 323–330
Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ; CAMELOT Investigators (2004): Effect of antihypertensive agents on cardiovascu- lar events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 292: 2217–2225
Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE et al (1996): Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 335: 1107–1114
Rothwell PM, Howard SC, Dolan E, OBrian E, Dobson JE, Dahlöf B, Poulter NR, Sever PS;
ASCOT-BPLA and MRC Trial Investigators (2010): Effects of ß blockers and calcium channel blockers on within-individual variability and risk of stroke. Lancet Neurol 9: 469–480
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002): The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981–2997
The DEFIANT-II Research Group (1997): Doppler flow and echocardiography in functional cardiac insufficiency: assessment of nisoldipine therapy. Results of the DEFIANT-II Study. Eur Heart J 18: 31-40 2–0
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Eschenhagen, T. (2015). Calciumantagonisten. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2015. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-47186-9_19
Download citation
DOI: https://doi.org/10.1007/978-3-662-47186-9_19
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-47185-2
Online ISBN: 978-3-662-47186-9
eBook Packages: Medicine (German Language)